nach oben

Current Osteoporosis Reports

Erschienen in:

01.03.2013 | Current Therapeutics (SL Silverman, Section Editor)

Adherence with Medications Used to Treat Osteoporosis: Behavioral Insights

verfasst von: John T. Schousboe

Erschienen in: Current Osteoporosis Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Non-persistence (never starting or stopping medication prematurely) and non-compliance (taking medication inappropriately) with fracture prevention medication among those at high risk of fracture remain significant barriers to optimal reduction of osteoporotic fractures. Current research suggest that for patients to persist and comply with prescriptions for fracture prevention medication, they need to believe that they are at significant risk of fracture, that the prescribed medication can safely reduce their risk of fracture without exposing them to long-term harm, that equally effective non-medicinal therapies are not available, and that they can successfully execute medication use in the context of their daily task demands. Further research is needed to understand; a) the mental models of osteoporosis, fractures, and medications used to treat osteoporosis that patients employ when making decisions as to whether or not to take fracture prevention medication; and b) how patients arbitrage information from various sources (health care providers, family, friends, and other sources) to formulate their beliefs about osteoporosis and medications used to treat it.

• Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728–40. This descriptive study shows how medication use behavior to prevent futrue adverse health events is similar across numerous medications and target diseases.

World Health Organization. Adherence to long-term therapies: Evidence for action 2003. 2003.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–7.PubMedCrossRef

Shah NR, Hirsch AG, Zacker C, Taylor S, Wood GC, Stewart WF. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med. 2009;24(2):233–7.PubMedCrossRef

Shah NR, Hirsch AG, Zacker C, Wood GC, Schoenthaler A, Ogedegbe G, et al. Predictors of firstfill adherence for patients with hypertension. Am J Hypertens. 2009;22(4):392–6.PubMedCrossRef

• Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, et al. Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284–90. This important study is the largest of the few showing the extent and importance of primary non-adherence to a variety of medications.PubMedCrossRef

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493–501.PubMedCrossRef

Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int. 2012;23(3):1075–82.PubMedCrossRef

Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80(7):856–61.

10.

Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract. 2006;12(5):522–8.PubMed

11.

Weiss TW, Henderson SC, McHorney CA, Cramer JA. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin. 2007;23(9):2193–203.PubMedCrossRef

12.

Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009;31(7):1497–510.PubMedCrossRef

13.

Hadji P, Ziller V, Gamerdinger D, Spieler W, Articus K, Baier M, et al. Quality of life and health status with zoledronic acid and generic alendronate–a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass. Osteoporos Int. 2012;23(7):2043–51.PubMedCrossRef

14.

Lee Y-K, Nho J-H, Ha Y-C, Koo K-H. Persistence with intravenous zoledronate in elderly patients with osteoporosis. Osteoporos Int. 2012;23(9):2329–33.PubMedCrossRef

15.

Solomon DH, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414–9.PubMedCrossRef

16.

Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17(6):922–8.PubMedCrossRef

17.

Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J. 2006;99(6):570–5.PubMedCrossRef

18.

Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int. 2006;17(11):1638–44.PubMedCrossRef

19.•

Landfeldt E, Strom O, Robbins S, Borgstrom F. Adherence to treatment of primary osteoporosis and its association to fractures–the Swedish Adherence Register Analysis (SARA). Osteoporos Int. 2012;23(2):433–43. An important study showing the temporal relationship between non-persistence with fracture prevention medications and incident fractures, using a comprehensive national database.PubMedCrossRef

20.

Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, et al. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int. 2012;23(4):1415–24.PubMedCrossRef

21.

Wamala S, Merlo J, Bostrom G, Hogstedt C, Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int J Qual Health Care. 2007;19(3):134–40.PubMedCrossRef

22.

Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, et al. Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int. 2003;14(10):808–13.PubMedCrossRef

23.

McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48(3):271–87.PubMedCrossRef

24.

Zambon A, Baio G, Mazzaglia G, Merlino L, Corrao G. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Saf. 2008;17(3):260–9.PubMedCrossRef

25.

Pressman A, Forsyth B, Ettinger B, Tosteson AN. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int. 2001;12(5):337–42.PubMedCrossRef

26.

Solomon DH, Levin E, Helfgott SM. Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. J Rheumatol. 2000;27(6):1496–500.PubMed

27.

Rubin SM, Cummings SR. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. Ann Intern Med. 1992;116(12 Pt 1):990–5.PubMed

28.

Silverman SL, Greenwald M, Klein RA, Drinkwater BL. Effect of bone density information on decisions about hormone replacement therapy: a randomized trial. Obstet Gynecol. 1997;89(3):321–5.PubMedCrossRef

29.

Pickney CS, Arnason JA. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int. 2005;16(9):1156–60.PubMedCrossRef

30.

Berecki-Gisolf J, Hockey R, Dobson A. Adherence to bisphosphonate treatment by elderly women. Menopause. 2008;15(5):984–90.PubMedCrossRef

31.

Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin. 2008;24(5):1337–44.PubMedCrossRef

32.

Gould ON, McDonald-Miszcak L, King B. Metacognition and medication adherence: how do older adults remember? Exp Aging Res. 1997;23:315–42.PubMedCrossRef

33.

Rosen MI, Beauvais JE, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Neuropsychological correlates of suboptimal adherence to metformin. J Behav Med. 2003;26(4):349–60.PubMedCrossRef

34.

Gray SL, Mahoney JE, Blough DK. Medication adherence in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 2001;35(5):539–45.PubMedCrossRef

35.

Salas M, In't Veld BA, van der Linden PD, Hofman A, Breteler M, Stricker BH. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther. 2001;70(6):561–6.PubMedCrossRef

36.

Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipidlowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25(6):445–51.PubMedCrossRef

37.

Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14(4):571–81.PubMedCrossRef

38.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–22.PubMedCrossRef

39.

• Patrick AR, Brookhart MA, Losina E, Schousboe JT, Cadarette SM, Mogun H, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251–9. The most detailed study to date exploring the details of the relationship between level and adherence to fracture prevention medication and incident fractures.

40.

Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19(6):811–8.PubMedCrossRef

41.

Sheehy O, Kindundu C, Barbeau M, LeLorier J. Adherence to weekly oral bisphosphonate therapy: cost of wasted drugs and fractures. Osteoporos Int. 2009;20(9):1583–94.PubMedCrossRef

42.

Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011;17(1):25–39.PubMed

43.

Sunyecz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int. 2008;19(10):1421–9.PubMedCrossRef

44.

Cadarette SM, Solomon DH, Katz JN, Patrick AR, Brookhart MA. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos Int. 2011;22(3):943–54.PubMedCrossRef

45.

Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care. 2011;49(5):427–35.PubMedCrossRef

46.

Curtis JR, Delzell E, Chen L, Black D, Ensrud K, Judd S, et al. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res. 2011;26(4):683–8.PubMedCrossRef

47.

Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115(3):209–16.PubMedCrossRef

48.

Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14(3):259–62.PubMed

49.

Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17(6):914–21.PubMedCrossRef

50.

Britten N, Ukoumunne OC, Boulton MG. Patients' attitudes to medicines and expectations for prescriptions. Health Expect. 2002;5(3):256–69.PubMedCrossRef

51.

Unson CG, Siccion E, Gaztambide J, Gaztambide S, Mahoney Trella P, Prestwood K. Nonadherence and osteoporosis treatment preferences of older women: a qualitative study. J Womens Health (Larchmt). 2003;12(10):1037–45.CrossRef

52.

Britten N. Patients' ideas about medicines: a qualitative study in a general practice population. Br J Gen Pract. 1994;44(387):465–8.PubMed

53.

Lin EH, Von Korff M, Ludman EJ, Rutter C, Bush TM, Simon GE, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25(5):303–10.PubMedCrossRef

54.

Benson J, Britten N. Patients' decisions about whether or not to take antihypertensive drugs: qualitative study. BMJ. 2002;325(7369):873.PubMedCrossRef

55.

Horne R, Weinman J, Hankins M. The Beliefs about Medications Questionnaire: the development of a new method for assessing the cognitive representation about medication. Psychol Health. 1999;14:1–24.CrossRef

56.

Donovan JL, Blake DR. Patient non-compliance: deviance or reasoned decision-making? Soc Sci Med. 1992;34(5):507–13.PubMedCrossRef

57.

Conrad P. The meaning of medications: another look at compliance. Soc Sci Med. 1985;20(1):29–37.PubMedCrossRef

58.

Shoemaker SJ, de Oliveira DR, Alves M, Ekstrand M. The medication experience: Preliminary evidence of its value for patient education and counseling on chronic medications. Patient Educ Couns. 2011;83(3):443–50.PubMedCrossRef

59.

Adams S, Pill R, Jones A. Medication, chronic illness and identity: the perspective of people with asthma. Soc Sci Med. 1997;45(2):189–201.PubMedCrossRef

60.

Dowell J, Hudson H. A qualitative study of medication-taking behaviour in primary care. Fam Pract. 1997;14(5):369–75.PubMedCrossRef

61.

• Sale JEM, Gignac MA, Hawker G, Frankel L, Beaton D, Bogoch E, et al. Decision to take osteoporosis medication in patients who have had a fracture and are 'high' risk for future fracture: a qualitative study. BMC Musculoskelet Disord. 2011;12:92. An important detailed descriptive study of how patients decide whether or not to accept a recommended prescription for fracture prevention medication.PubMedCrossRef

62.

Janz N, Becker M. The health belief model: a decade later. Heal Educ Q. 1984;11(1):1–47.CrossRef

63.

Connor M, Sparks P. The theory of planned behavior and health behaviors. In: Connor M, Norman P, editors. Predicting health behavior. Philadelphia: Open University Press; 1995. p. 121–62.

64.

Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognitive interactions. Cogn Ther Res. 1992;16(2):143–63.CrossRef

65.

Bandura A. Social foundations of thought and action. A social cognitive theory. Englewood Cliffs: Prentice-Hall, Inc.; 1986.

66.

Buglar ME, White KM, Robinson NG. The role of self-efficacy in dental patients' brushing and flossing: testing an extended Health Belief Model. Patient Educ Couns. 2010;78(2):269–72.PubMedCrossRef

67.

Bylund CL, Galvin KM, Dunet DO, Reyes M. Using the extended health belief model to understand siblings' perceptions of risk for hereditary hemochromatosis. Patient Educ Couns. 2011;82(1):36–41.PubMedCrossRef

68.

Gillibrand R, Stevenson J. The extended health belief model applied to the experience of diabetes in young people. Br J Health Psychol. 2006;11(Pt 1):155–69.PubMedCrossRef

69.

Cline RR, Farley JF, Hansen RA, Schommer JC. Osteoporosis beliefs and antiresorptive medication use. Maturitas. 2005;50(3):196–208.PubMedCrossRef

70.

McHorney CA, Schousboe JT, Cline RR, Weiss TW. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin. 2007;23(12):3137–52.PubMedCrossRef

71.

Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008;23(11):1815–21.PubMedCrossRef

72.

• Schousboe JT, Dowd BE, Davison ML, Kane RL. Association of medication attitudes with non-persistence and non-compliance with medication to prevent fractures. Osteoporos Int. 2010;21(11):1899–909. This study is unique in that it shows the relative importance of different medication attitudes and beliefs, included perceived self efficacy on self-reported persistence and compliance with fracture prevention medications.

73.

• Schousboe JT, Davison ML, Dowd B, Thiede Call K, Johnson P, Kane RL. Predictors of patients' perceived need for medication to prevent fracture. Med Care. 2011;49(3):273–80. This studyis unique in that it illustrates the relative importance of the quality of the patientphysician relationship and objective indicators of fracture risk, adjusted for each other, on patient perceived necessity of fracture prevention medication.

74.

Solomon DH, Brookhart MA, Tsao P, Sundaresan D, Andrade SE, Mazor K, et al. Predictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction rule. Osteoporos Int. 2011;22(6):1737–43.PubMedCrossRef

75.

Bandura A. Human agency in social cognitive theory. Am Psychol. 1989;44(9):1175–84.PubMedCrossRef

76.

Resnick B, Wehren L, Orwig D. Reliability and validity of the self-efficacy and outcome expectations for osteoporosis medication adherence scales. Orthop Nurs. 2003;22(2):139–47.PubMedCrossRef

77.

Bloom G, Standing H, Lloyd R. Markets, information asymmetry and health care: towards new social contracts. Soc Sci Med. 2008;66(10):2076–87.PubMedCrossRef

78.

Thorne SE, Robinson CA. Reciprocal trust in health care relationships. J Adv Nurs. 1988;13(6):782–9.PubMedCrossRef

79.

Hall MA, Dugan E, Zheng B, Mishra AK. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q. 2001;79(4):613–39. v.PubMedCrossRef

80.

Goff SL, Mazor KM, Meterko V, Dodd K, Sabin J. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med. 2008;23(3):236–41.PubMedCrossRef

81.

Buller M, Buller D. Physicians' communication style and patient satisfaction. J Heal Soc Behav. 1987;28:375–88.CrossRef

82.

Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.PubMedCrossRef

83.

Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patientphysician congruence and patient outcomes. Patient Educ Couns. 2005;57(3):308–14.PubMedCrossRef

84.

• Douglas F, Petrie KJ, Cundy T, Horne A, Gamble G, Grey A. Differing perceptions of intervention thresholds for fracture risk: a survey of patients and doctors. Osteoporos Int. 2012;23(8):2135–40. This study is an important, recent documentation of how patients and physicians perceive fracture risks and use of medications to lower those risks differently.PubMedCrossRef

85.

Cadarette SM, Carney G, Baek D, Gunraj N, Paterson JM, Dormuth CR. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage. Osteoporos Int. 2012;23(4):1475–80.PubMedCrossRef

86.

Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of a limit on Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–5.PubMedCrossRef

87.

Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–50.PubMedCrossRef

88.

Zafran N, Liss Z, Peled R, Sherf M, Reuveni H. Incidence and causes for failure of treatment of women with proven osteoporosis. Osteoporos Int. 2005;16(11):1375–83.PubMedCrossRef

89.

Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.PubMedCrossRef

90.

Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150(9):1881–4.PubMedCrossRef

91.

Wroe AL. Intentional and unintentional nonadherence: a study of decision making. J Behav Med. 2002;25(4):355–72.PubMedCrossRef

92.

Silverman SL, Schousboe JT, Gold DT. Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporos Int. 2011;22(1):21–6.PubMedCrossRef

93.

Kripalani S, Gatti ME, Jacobson TA. Association of age, health literacy, and medication management strategies with cardiovascular medication adherence. Patient Educ Couns. 2010;81(2):177–81.PubMedCrossRef

94.

Berkman ND, Sheridan SL, Donahue KE, Halpern DJ, Crotty K. Low health literacy and health outcomes: an updated systematic review. Ann Intern Med. 2011;155(2):97–107.PubMed

95.

Elliott RA, Shinogle JA, Peele P, Bhosle M, Hughes DA, Elliott RA, et al. Understanding medication compliance and persistence from an economics perspective. Value Health. 2008;11(4):600–10.PubMedCrossRef

96.

Roelofsma PH, van der Pligt J. On the psychology of time preference and human decisions: introduction to the special issue. Acta Psychol (Amst). 2001;108(2):91–3.CrossRef

97.

Read D, Loewenstein G. Time and decision: introduction to the special issue. J Behav Decis Mak. 2000;13:141–4.CrossRef

98.

Sozou PD, Seymour RM, Sozou PD, Seymour RM. Augmented discounting: interaction between ageing and time-preference behaviour. Proc R Soc London, Ser B. 2003;270(1519):1047–53.CrossRef

Titel: Adherence with Medications Used to Treat Osteoporosis: Behavioral Insights
verfasst von: John T. Schousboe
Publikationsdatum: 01.03.2013
Verlag: Current Science Inc.
Erschienen in: Current Osteoporosis Reports / Ausgabe 1/2013
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-013-0133-8

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Aromatase Inhibitor Adjuvant Chemotherapy of Breast Cancer Results in Cancer Therapy Induced Bone Loss

Prostate Cancer and Osteoporosis

Bisphosphonate Drug Holiday: Choosing Appropriate Candidates

Best Practices in Secondary Fracture Prevention: Fracture Liaison Services

Imaging Technologies for Assessment of Skeletal Health in Men